Spectrum Pharmaceuticals (NASDAQ:SPPI) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued on Thursday. They currently have a $8.60 target price on the stock. Zacks‘s price target suggests a potential upside of 7.50% from the company’s current price. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) net profit margin is -57.10% and weekly performance is 10.09%. On last trading day company shares ended up $8.51. Analysts mean target price for the company is $ 10.92. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) distance from 50-day simple moving average (SMA50) is 15.68%.
On June 4, 2014, The Board of Directors of MiMedx Group Inc (NASDAQ:MDXG), announce that the Board applauds the dismissal of the lawsuit brought by the Securities and Exchange Commission (“SEC”) against the Company’s Chairman and CEO, Parker H. “Pete” Petit. MiMedx Group Inc (NASDAQ:MDXG) shares advanced 6.00% in last trading session and ended the day on $6.36. MDXG Gross Margin is 84.50% and its return on assets is -5.30%. MiMedx Group Inc (NASDAQ:MDXG) quarterly performance is -12.03%.
On May 30, Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo’s zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs). Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares moved up 7.34% in last trading session and was closed at $15.51, while trading in range of $14.29 – $15.71. Sangamo Biosciences, Inc. (NASDAQ:SGMO) year to date (YTD) performance is 11.66%.
Immunomedics, Inc. (NASDAQ:IMMU) announced that IMMU-132, the Company’s antibody-drug conjugate (ADC) for solid cancer therapy, has received orphan drug status from the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. Immunomedics, Inc. (NASDAQ:IMMU) ended the last trading day at $3.74. Company weekly volatility is calculated as 4.51% and price to cash ratio as 14.94. {Full Company Name} showed a positive weekly performance of 12.65%.
orizon Pharma (NASDAQ:HZNP) CFO Vaere Robert De sold 12,939 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $12.94, for a total value of $167,430.66. Following the completion of the sale, the chief financial officer now directly owns 88,555 shares in the company, valued at approximately $1,145,902. Horizon Pharma Inc (NASDAQ:HZNP) shares advanced 5.59% in last trading session and ended the day on $15.29. HZNP Gross Margin is 84.60%and its return on assets is -153.40%. Horizon Pharma Inc (NASDAQ:HZNP) quarterly performance is 12.59%.
Leave a Reply